Title : Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.

Pub. Date : 1997 Jun

PMID : 9241661






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the case of CYP2C9, a Ile359 to Leu mutation associated with poor metabolism of the hypoglycemic drug tolbutamide decreased catalytic efficiency toward cyclophosphamide by increasing the apparent Km, whereas the same mutation reduced the efficiency of this P450 toward ifosfamide by decreasing the Vmax. Tolbutamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens